Comparative Antiresorptive Efficacy Discontinuation of Denosumab

  • STATUS
    Not Recruiting
  • End date
    Jan 1, 2025
  • participants needed
    71
  • sponsor
    Massachusetts General Hospital
Updated on 13 June 2022
denosumab
osteoporosis
bisphosphonate
RANKL
alendronate
teriparatide
raloxifene
postmenopausal osteoporosis
abaloparatide

Summary

Osteoporosis remains a significant healthcare burden for the United States. Current FDA-approved osteoporosis treatments include teriparatide, abaloparatide, bisphosphonates, denosumab, and raloxifene.

Denosumab is a fully human monoclonal antibody that specifically binds to receptor activator of nuclear factor kappa-B ligand (RANKL). Denosumab potently suppresses osteoclastic activity but bone turnover rapidly normalizes and bone turnover marker levels can rebound above baseline levels after the drug is discontinued.

This study will help us determine the optimal duration and relative efficacy of two oral antiresorptive medications that are FDA-approved for treatment of postmenopausal osteoporosis (alendronate and raloxifene) in preventing the rebound increase in bone turnover that occurs after denosumab discontinuation.

Details
Condition Osteopenia, Osteopenia, Osteoporosis, Osteoporosis, Postmenopausal osteoporosis, Post-Menopausal Osteoporosis, Post-Menopausal Osteopenia, Post-Menopausal Osteoporosis, Post-Menopausal Osteopenia
Treatment Alendronate, raloxifene, Denosumab
Clinical Study IdentifierNCT03623633
SponsorMassachusetts General Hospital
Last Modified on13 June 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note